Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | ERN1 | O75460 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9844924 | 0.87 | KDM4E (0.48) | HSD17B10KDM4EMAPTTSHRALDH1A1 | |
| SCHEMBL11054505 | 0.86 | HSD17B10 (0.41) | HSD17B10KDM4EMAPTTSHRALDH1A1 | |
| SCHEMBL1668962 | 0.82 | CA2 (0.59) | HSD17B10KDM4EMAPTTSHRALDH1A1 | |
| SCHEMBL30366773 | 0.80 | KDM4E (0.46) | HSD17B10KDM4EMAPTTSHRALDH1A1 | |
| SCHEMBL6360290 | 0.80 | CSNK2A2 (0.40) | HSD17B10KDM4EMAPTTSHRALDH1A1 | |
| SCHEMBL3453136 | 0.78 | BCAT2 (0.50) | HSD17B10KDM4EMAPTTSHRALDH1A1 | |
| SCHEMBL7095311 | 0.77 | SELL (0.59) | HSD17B10KDM4EMAPTTSHRALDH1A1 | |
| SCHEMBL1956878 | 0.77 | KDM4E (0.43) | HSD17B10KDM4EMAPTTSHRALDH1A1 | |
| SCHEMBL28877395 | 0.77 | ALDH1A1 (0.38) | HSD17B10KDM4EMAPTTSHRALDH1A1 | |
| SCHEMBL28840578 | 0.77 | KDM4E (0.43) | HSD17B10KDM4EMAPTTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071104-A1 | Anionic Curable Compositions | DESIGNER MOLECULES INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260071103-A1 | Anionic Curable Compositions | DESIGNER MOLECULES INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-3331959-B1 | ANIONIC CURABLE COMPOSITIONS | DESIGNER MOLECULES INC (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-108291122-B | Anionically curable compositions | 设计分子有限公司 | 2021-01-05 | — | — | CN | disclosed |
| US-20180237668-A1 | ANIONIC CURABLE COMPOSITIONS | DESIGNER MOLECULES, INC. | 2018-08-23 | — | — | US | disclosed |
| EP-3331959-A1 | ANIONIC CURABLE COMPOSITIONS | Designer Molecules, Inc. (US) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017027482-A1 | ANIONIC CURABLE COMPOSITIONS | DESIGNER MOLECULES, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| US-7964697-B2 | Polyarylether membranes | GENERAL ELECTRIC COMPANY (US) | 2011-06-21 | — | — | US | disclosed |
| US-7834134-B2 | Polyarylethers, blends and methods for making | GENERAL ELECTRIC COMPANY (US) | 2010-11-16 | — | — | US | disclosed |
| WO-2010019331-A1 | POLYARYLETHER MEMBRANES | GENERAL ELECTRIC COMPANY (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041838-A1 | POLYARYLETHERS, BLENDS AND METHODS FOR MAKING | BL TECHNOLOGIES, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100041837-A1 | POLYARYLETHERS, BLENDS AND METHODS FOR MAKING | GENERAL ELECTRIC COMPANY | 2010-02-18 | — | — | US | disclosed |
| US-20100041853-A1 | POLYARYLETHER MEMBRANES | BL TECHNOLOGIES, INC. | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071104-A1 | Anionic Curable Compositions | VCL, ITGA8, GABRE | HSD17B10 4509/4885KDM4E 41/4885MAPT 1294/4885 |
| US-20260071103-A1 | Anionic Curable Compositions | CDH1, ESD, SETD2 | HSD17B10 4395/4885KDM4E 41/4885MAPT 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.